Study of Enfuvirtide in HIV-Positive Subjects
Primary Purpose
HIV Infections, AIDS
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Fuzeon
Sponsored by
About this trial
This is an interventional treatment trial for HIV Infections
Eligibility Criteria
Inclusion Criteria: - Exclusion Criteria: -
Sites / Locations
- SFBC
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00086710
First Posted
July 8, 2004
Last Updated
June 23, 2005
Sponsor
Trimeris
Collaborators
Hoffmann-La Roche
1. Study Identification
Unique Protocol Identification Number
NCT00086710
Brief Title
Study of Enfuvirtide in HIV-Positive Subjects
Official Title
An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration
Study Type
Interventional
2. Study Status
Record Verification Date
April 2004
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Trimeris
Collaborators
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, AIDS
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Fuzeon
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Facility Information:
Facility Name
SFBC
City
Miami
State/Province
Florida
ZIP/Postal Code
33181
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of Enfuvirtide in HIV-Positive Subjects
We'll reach out to this number within 24 hrs